Research advances on L-DOPA-induced dyskinesia: from animal models to human disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Research advances on L-DOPA-induced dyskinesia: from animal models to human disease
Authors
Keywords
-
Journal
NEUROLOGICAL SCIENCES
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-17
DOI
10.1007/s10072-020-04333-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia
- (2019) Rhyomi C. Sellnow et al. Acta Neuropathologica Communications
- Cannabinoid receptor as a potential therapeutic target for Parkinson’s Disease
- (2019) Himadri Shekhaar Baul et al. BRAIN RESEARCH BULLETIN
- Should there be less emphasis on levodopa‐induced dyskinesia in Parkinson's disease?
- (2019) K. Ray Chaudhuri et al. MOVEMENT DISORDERS
- Pathophysiological clues to therapeutic applications of glutamate mGlu5 receptor antagonists in levodopa-induced dyskinesia
- (2019) Shayan Pourmirbabaei et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Parkinson's disease: Mechanisms, translational models and management strategies
- (2019) Chand Raza et al. LIFE SCIENCES
- Updates and advances in the treatment of Parkinson disease
- (2019) Michael W Hayes et al. MEDICAL JOURNAL OF AUSTRALIA
- Non-motor symptoms of Parkinson’s disease: dopaminergic basis or not?
- (2019) Chanwoo Kim NEUROLOGICAL SCIENCES
- Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
- (2019) Del Bello et al. Biomolecules
- Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review
- (2019) De-Qi Jiang et al. NEUROLOGICAL SCIENCES
- Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
- (2019) Paolo Calabresi et al. NEUROBIOLOGY OF DISEASE
- Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease by metabolomic technology
- (2018) Yong Wang et al. BEHAVIOURAL BRAIN RESEARCH
- Update in therapeutic strategies for Parkinsonʼs disease
- (2018) Jaime Kulisevsky et al. CURRENT OPINION IN NEUROLOGY
- mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia
- (2018) Irene Sebastianutto et al. CURRENT OPINION IN PHARMACOLOGY
- Dyskinesias and levodopa therapy: why wait?
- (2018) Michele Matarazzo et al. JOURNAL OF NEURAL TRANSMISSION
- The striatal cholinergic system in l-dopa-induced dyskinesias
- (2018) X. A. Perez et al. JOURNAL OF NEURAL TRANSMISSION
- Levodopa-induced dyskinesia: clinical features, incidence, and risk factors
- (2018) Tai N. Tran et al. JOURNAL OF NEURAL TRANSMISSION
- Dopamine receptors: homomeric and heteromeric complexes in l-DOPA-induced dyskinesia
- (2018) Oscar Solís et al. JOURNAL OF NEURAL TRANSMISSION
- Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3−/−Mice, a Genetic Model of Parkinson's Disease
- (2018) Luz M. Suarez et al. JOURNAL OF NEUROSCIENCE
- Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey
- (2018) Nicolas Veyres et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Medical and surgical management of advanced Parkinson's disease
- (2018) Angelo Antonini et al. MOVEMENT DISORDERS
- Animal models of l -dopa-induced dyskinesia in Parkinson's disease
- (2018) M. Angela Cenci et al. MOVEMENT DISORDERS
- Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia
- (2018) Melissa Crabbé et al. NEUROBIOLOGY OF AGING
- Opioidergic Modulation of Striatal Circuits, Implications in Parkinson's Disease and Levodopa Induced Dyskinesia
- (2018) Stefania Sgroi et al. Frontiers in Neurology
- The importance of preclinical diagnostics in Parkinson disease
- (2018) Sneha Mantri et al. PARKINSONISM & RELATED DISORDERS
- Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale
- (2018) Attila Makkos et al. PARKINSONISM & RELATED DISORDERS
- Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts
- (2018) Alberto J. Espay et al. ANNALS OF NEUROLOGY
- Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation
- (2018) Michael H. Li et al. Journal of NeuroEngineering and Rehabilitation
- Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
- (2018) Khosro Jamebozorgi et al. MOLECULAR NEUROBIOLOGY
- Using Wearable Technology to Generate Objective Parkinson’s Disease Dyskinesia Severity Score: Possibilities for Home Monitoring
- (2017) Mehdi Delrobaei et al. IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING
- Non-human primate models of PD to test novel therapies
- (2017) Marc Morissette et al. JOURNAL OF NEURAL TRANSMISSION
- Animal models of l-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse
- (2017) Elisabetta Tronci et al. JOURNAL OF NEURAL TRANSMISSION
- Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease
- (2017) Ledia F. Hernández et al. MOVEMENT DISORDERS
- Dysregulation of BET proteins in levodopa-induced dyskinesia
- (2017) David A. Figge et al. NEUROBIOLOGY OF DISEASE
- Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias
- (2017) Jennifer Stanic et al. NEUROBIOLOGY OF DISEASE
- How serotonin receptors regulate morphogenic signalling in neurons
- (2017) Alexander Wirth et al. PROGRESS IN NEUROBIOLOGY
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)
- (2017) Rajesh Pahwa et al. JAMA Neurology
- Opioid system in L-DOPA-induced dyskinesia
- (2017) Jing Pan et al. Translational Neurodegeneration
- Are rodent models of Parkinson’s disease behaving as they should?
- (2017) Siv Vingill et al. BEHAVIOURAL BRAIN RESEARCH
- Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia
- (2016) David A. Figge et al. JOURNAL OF NEUROSCIENCE
- A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
- (2016) François Tison et al. MOVEMENT DISORDERS
- Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists
- (2016) Irene Sebastianutto et al. NEUROBIOLOGY OF DISEASE
- Neurobehavioral Anomalies in the Pitx3/ak Murine Model of Parkinson’s Disease and MPTP
- (2015) Mohammed Filali et al. BEHAVIOR GENETICS
- Serotonin in Parkinson's disease
- (2015) Marios Politis et al. BEHAVIOURAL BRAIN RESEARCH
- A new quantitative rating scale for dyskinesia in nonhuman primates
- (2015) Lisa F. Potts et al. BEHAVIOURAL PHARMACOLOGY
- Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
- (2015) Per Svenningsson et al. BRAIN
- Rotigotine is a potent agonist at dopamine D1receptors as well as at dopamine D2and D3receptors
- (2015) Martyn Wood et al. BRITISH JOURNAL OF PHARMACOLOGY
- Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients
- (2015) Rajeev Kumar et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Gene Expression Analyses Identify Narp Contribution in the Development of L-DOPA-Induced Dyskinesia
- (2015) F. Charbonnier-Beaupel et al. JOURNAL OF NEUROSCIENCE
- New treatments for levodopa-induced motor complications
- (2015) Olivier Rascol et al. MOVEMENT DISORDERS
- Pitx3 deficiency produces decreased dopamine signaling and induces motor deficits in Pitx3(−/−) mice
- (2015) Weidong Le et al. NEUROBIOLOGY OF AGING
- Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
- (2015) Matthieu F. Bastide et al. PROGRESS IN NEUROBIOLOGY
- NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients
- (2015) Manuela Mellone et al. Frontiers in Cellular Neuroscience
- Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
- (2014) Eva Schaeffer et al. CNS DRUGS
- Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease
- (2014) Manuela Pilleri et al. Expert Opinion On Drug Safety
- Striatal Cholinergic Cell Ablation Attenuates L-DOPA Induced Dyskinesia in Parkinsonian Mice
- (2014) L. Won et al. JOURNAL OF NEUROSCIENCE
- Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial
- (2014) PD MED Collaborative Group LANCET
- Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications
- (2014) M. Angela Cenci Frontiers in Neurology
- Modeling dyskinesia in animal models of Parkinson disease
- (2013) Nicolas Morin et al. EXPERIMENTAL NEUROLOGY
- Animal Models of Parkinson’s Disease: A Gateway to Therapeutics?
- (2013) Weidong Le et al. Neurotherapeutics
- Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
- (2012) M. A. Cenci et al. CNS & Neurological Disorders-Drug Targets
- A critique of available scales and presentation of the non-human primate dyskinesia rating scale
- (2012) Susan H. Fox et al. MOVEMENT DISORDERS
- Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
- (2012) P. A. LeWitt et al. NEUROLOGY
- Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease
- (2012) J. Guridi et al. Parkinsons Disease
- The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
- (2011) Susan H. Fox et al. MOVEMENT DISORDERS
- The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys
- (2011) Laurent Grégoire et al. PARKINSONISM & RELATED DISORDERS
- Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease
- (2010) Colleen M. Niswender et al. Annual Review of Pharmacology and Toxicology
- Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats
- (2010) Yoshihiro Tani et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- l-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata
- (2010) Claudia Rangel-Barajas et al. NEUROBIOLOGY OF DISEASE
- Levodopa-induced dyskinesias and their management
- (2008) Francesca Sorbo et al. JOURNAL OF NEUROLOGY
- Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism
- (2008) John G. Nutt et al. MOVEMENT DISORDERS
- Placebo influences on dyskinesia in Parkinson's disease
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys
- (2007) Pershia Samadi et al. NEUROBIOLOGY OF AGING
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started